Axsome Logo.png
Axsome Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
09 août 2021 07h05 HE | Axsome Therapeutics, Inc.
Company to host conference call today at 8:00 AM Eastern NEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies...
Axsome Logo.png
Axsome Therapeutics Announces AXS-05 Achieves Primary and Key Secondary Endpoints in the MERIT Phase 2 Trial in Treatment Resistant Depression
09 août 2021 07h00 HE | Axsome Therapeutics, Inc.
AXS-05 significantly delayed the time to relapse of depression compared to placebo (p=0.002, primary endpoint) AXS-05 significantly prevented relapse of depression over at least 6 months compared to...
Axsome Logo.png
Axsome Therapeutics to Report Second Quarter 2021 Financial Results on August 9, 2021
15 juil. 2021 07h00 HE | Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Monday, August 9, 2021 at 8:00 AM Eastern Time NEW YORK, July 15, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Axsome Logo.png
Axsome Therapeutics Announces Planned NDA Submission for AXS-14 for the Management of Fibromyalgia
15 juin 2021 07h00 HE | Axsome Therapeutics, Inc.
        Submission anticipated in 4Q 2022 NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the...
axsomelogo-468x57.jpg
Axsome Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
10 mai 2021 07h00 HE | Axsome Therapeutics, Inc.
Company to host conference call today at 8:00 AM Eastern NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies...
axsomelogo-468x57.jpg
Axsome Therapeutics Joins Mental Health America and other Advocacy Organizations in Raising Awareness and Providing Support for Mental Health During Mental Health Month
07 mai 2021 07h00 HE | Axsome Therapeutics, Inc.
NEW YORK, May 07, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) is joining Mental Health America (MHA) and other advocacy organizations in observing May is Mental Health Month,...
axsomelogo-468x57.jpg
Axsome Therapeutics to Report First Quarter 2021 Financial Results on May 10, 2021
27 avr. 2021 07h00 HE | Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Monday, May 10, 2021 at 8:00 AM Eastern Time NEW YORK, April 27, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical...
axsomelogo-468x57.jpg
Axsome Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for AXS-05 for Treatment of Major Depressive Disorder
26 avr. 2021 06h00 HE | Axsome Therapeutics, Inc.
FDA grants Priority Review and sets PDUFA action goal date of August 22, 2021 NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company...
axsomelogo-468x57.jpg
Axsome Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
01 mars 2021 07h00 HE | Axsome Therapeutics, Inc.
Company to host conference call today at 8:00 AM Eastern NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel...
axsomelogo-468x57.jpg
Axsome Therapeutics to Present at Upcoming Investor Conferences
19 févr. 2021 07h00 HE | Axsome Therapeutics, Inc.
NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...